Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis

Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis

Background: Immunotherapy is an emerging antitumor therapy that can improve the survival of patients with advanced non-small-cell lung cancer (NSCLC). However, only about 20% of NSCLC patients can benefit from this treatment. At present, whether patients with driving gene-positive NSCLC can benefit...

Full description

Bibliographic Details
Main Authors:	Jiayan Chen, Wanjun Lu, Mo Chen, Zijing Cai, Ping Zhan, Xin Liu, Suhua Zhu, Mingxiang Ye, Tangfeng Lv, Jiawen Lv, Yong Song, Dong Wang
Format:	Article
Language:	English
Published:	SAGE Publishing 2024-02-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/17588359231225036

Similar Items

Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer
by: Natalie I. Vokes, et al.
Published: (2023-03-01)

LKB1 dictates sensitivity to immunotherapy through Skp2-mediated ubiquitination of PD-L1 protein in non-small cell lung cancer
by: Wei Liu, et al.
Published: (2024-12-01)

The Predictive Value of Clinical and Molecular Characteristics or Immunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
by: Yangyang Xu, et al.
Published: (2021-09-01)

Effect of Adjuvant Chemotherapy on Survival of Patients With 8th Edition Stage IB Non-Small Cell Lung Cancer
by: Yangyang Xu, et al.
Published: (2022-01-01)

Effect of Different Antitumor Regimens on Incidence and Severity of Corona Virus  Disease 2019 Pneumonia in Lung Cancer Patients:  A Single-center Retrospective Study
by: Wanjun LU, et al.
Published: (2023-06-01)

Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer
by: Jing Cheng, et al.
Published: (2025-02-01)

Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
by: Donghui Wang, et al.
Published: (2021-03-01)

FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer
by: Dong Wang, et al.
Published: (2022-09-01)

Evaluation of the Lung Immune Prognostic Index in Non-Small Cell Lung Cancer Patients Treated With Systemic Therapy: A Retrospective Study and Meta-Analysis
by: Litang Huang, et al.
Published: (2021-06-01)

Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer
by: Xinying Li, et al.
Published: (2021-08-01)

1140 Labyrinthin as a potential neoantigen for oncogene-driven and non-oncogene-driven lung adenocarcinomas
by: Shuai Chen, et al.
Published: (2023-11-01)

Expression and Prognostic Value of AKT2 in Non-small Cell Lung Cancer
by: Yanling LV, et al.
Published: (2011-05-01)

Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small-cell lung cancer
by: Haowei Wang, et al.
Published: (2025-02-01)

Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer.
by: Tangfeng Lv, et al.
Published: (2012-01-01)

Durvalumab-induced organizing pneumonia in extensive-stage small cell lung cancer: A case report and literature review
by: Guoxin Wang, MD, et al.
Published: (2025-05-01)

Clinical impact of first‐line PD‐1 or PD‐L1 inhibitors combined with chemotherapy in extensive‐stage small cell lung cancer patients: A real‐world multicenter propensity score‐matched study
by: Jingyuan Xie, et al.
Published: (2023-05-01)

An oncogene regulating chromatin favors response to immunotherapy<subtitle>Oncogene CHAF1A and immunotherapy outcomes</subtitle>
by: Leqian Ying, et al.
Published: (2024-12-01)

Immunotherapy Advances in Small Cell Lung Cancer
by: Yangyang XU, et al.
Published: (2020-11-01)

CD39+ Regulatory T Cells Attenuate Lipopolysaccharide-Induced Acute Lung Injury via Autophagy and the ERK/FOS Pathway
by: Cen Chen, et al.
Published: (2021-01-01)

STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer
by: Ilaria Attili, et al.
Published: (2018-03-01)

KRAS oncogene in lung cancer: focus on molecularly driven clinical trials
by: Emmanuelle Kempf, et al.
Published: (2016-03-01)

Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer: a Bayesian network meta-analysis
by: Huijuan Li, et al.
Published: (2023-10-01)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
by: Yijia Du, et al.
Published: (2022-12-01)

Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis
by: Xiaodi Wu, et al.
Published: (2024-02-01)

Heterogeneity between subgroups of first-line chemoimmunotherapy for extensive-stage small cell lung cancer patients: a meta-analysis and systematic review
by: Wenwen Kang, et al.
Published: (2024-10-01)

Oncogenic viral antigens for engineered T cell immunotherapy: Challenges and opportunities
by: Haipeng Zhang, et al.
Published: (2023-12-01)

ALKBH5 promotes non-small cell lung cancer progression and susceptibility to anti-PD-L1 therapy by modulating interactions between tumor and macrophages
by: Xin Hua, et al.
Published: (2024-06-01)

Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer
by: Mo Shen, et al.
Published: (2022-01-01)

Association of MUC19 Mutation With Clinical Benefits of Anti-PD-1 Inhibitors in Non-small Cell Lung Cancer
by: Li Zhou, et al.
Published: (2021-03-01)

Chinese expert consensus on immunotherapy for advanced non-small cell lung cancer with oncogenic driver mutations (2023 edition)
by: The Society of Cancer Precision Medicine of Chinese Anti-Cancer Association; The Lung Cancer Expert Group of Chinese Medical Association Publishing House, et al.
Published: (2024-05-01)

The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer
by: Barbara Melosky, et al.
Published: (2025-01-01)

An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer
by: Adrian Vallejo, et al.
Published: (2017-02-01)

Progressive Disease with Mixed Response After Immunotherapy in Non-Small Cell Lung Cancer
by: Lv J, et al.
Published: (2024-09-01)

Comparison of antifungal drugs in the treatment of invasive pulmonary aspergillosis: a systematic review and network meta-analysis
by: Jing Cheng, et al.
Published: (2024-12-01)

First‐line chemoimmunotherapy for patients with small‐cell lung cancer and interstitial lung abnormality: CIP risk and prognostic analysis
by: Yu Li, et al.
Published: (2024-12-01)

The O-glycosylating enzyme GALNT2 acts as an oncogenic driver in non-small cell lung cancer
by: Qing Hu, et al.
Published: (2022-09-01)

Molecular Factors Related to Gefitinib Efficacy in Advanced Non-small Cell Lung Cancer
by: Tao ZHOU, et al.
Published: (2010-03-01)

Research Progress on Predictive Biomarkers of Immunotherapy Efficacy in Non-small Cell Lung Cancer
by: Tiansheng SUN, et al.
Published: (2024-06-01)

Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non–small cell lung cancer
by: Yu Xin, et al.
Published: (2024-02-01)

Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer
by: Feifei Dou, et al.
Published: (2018-05-01)